Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Portfolio Pulse from
Avecho Biotechnology Limited has entered a ten-year exclusive development and licensing agreement with Sandoz Group AG to commercialize Avecho's CBD capsule for insomnia in Australia. Avecho will receive upfront, milestone, and royalty payments, while Sandoz will handle commercial sales in Australia.
March 03, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sandoz Group AG has signed a ten-year exclusive agreement with Avecho to commercialize CBD capsules for insomnia in Australia, potentially boosting its market presence in the growing CBD sector.
The agreement allows Sandoz to commercialize a new CBD product in a growing market, potentially increasing its revenue and market share in the CBD sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80